China’s Medical Services Expected To Double in 2008
This article was originally published in PharmAsia News
The imminent implementation of the State Council's three national technological projects - of which pharmaceutical manufacturing and innovation is one - will see increased funding for R&D for treatment and prevention of major diseases. The government's medical subsidies for individual citizen's medical insurance and services will double this year, leading to an estimated 653 billion yuan consumer market for health care. The scheme, riding on the back of an aging population, will drive the demand and widespread use of generic drugs. Industry analysts see three key trends arising: more mergers and acquisitions; greater role of leading pharmaceutical corporations; and rapid increase in domestic generic drug manufacturing for both local and international markets. (Click here for more)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?